All In Biotech

Free tool

FAERS Monitor: Qutenza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022395 or its brand name (Qutenza, Capsaicin). Reports on generic versions are filed under their own applications.

Reports

3,257

Serious

1,865

57% of reports

Hospitalization

610

Death reported

156

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • application site pain607
  • pain424
  • drug ineffective377
  • burning sensation330
  • pain in extremity215
  • application site erythema165
  • fatigue159
  • off label use145
  • insomnia110
  • dyspnoea105
  • paraesthesia100
  • weight increased100
  • nausea96
  • hypoaesthesia91
  • dizziness86

Reports by year received

View as table
YearReports
200416
200524
200621
200723
20086
200913
201017
201144
201286
201378
2014117
2015105
2016133
2017114
2018137
2019173
2020130
2021183
2022197
2023250
2024326
2025724
2026340

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,902 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site painSignal607183.0170.1106,757
application site erythemaSignal16540.935.26,351
burning sensationSignal33030.527.69,384
pain in extremitySignal2154.74.1634
painSignal4244.54.11,168
paraesthesiaSignal1004.13.4234
hypoaesthesiaSignal913.93.2197
weight increasedSignal1002.92.4122
insomniaSignal1102.72.2114
drug ineffective3771.81.7155
fatigue1591.31.112
dyspnoea1051.21.03
dizziness861.10.91
off label use1451.10.91
nausea960.80.66

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.